3 April 2020 Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase III clinical trial to treat cytokine storm in patients with severe Covid-19 pneumonia.
The planned trial will compare a combination of Jakavi and standard-of-care (SoC) therapy against SoC alone. Read the full story here. Amgen has partnered with Adaptive Biotechnologies to discover and develop fully human neutralising antibodies targeting the SARS-CoV-2 virus that could prevent or treat Covid-19.
The alliance will combine Adaptive’s immune medicine platform with Amgen’s immunology and antibody development expertise. Read the full story here.